Kyverna Therapeutics, Inc. Common Stock Total Assets
Kyverna Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Kyverna Therapeutics, Inc. Common Stock (KYTX) holds total assets worth $257.02 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see KYTX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Total assets of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See current stock price of Kyverna Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Kyverna Therapeutics, Inc. Common Stock - Asset Composition Analysis
Kyverna Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Kyverna Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Kyverna Therapeutics, Inc. Common Stock's total assets of $257.02 Million consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Kyverna Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Kyverna Therapeutics, Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kyverna Therapeutics, Inc. Common Stock's current assets represent 96.3% of total assets in 2025, an increase from 90.2% in 2021.
- Cash Position: Cash and equivalents constituted 42.2% of total assets in 2025, down from 89.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kyverna Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Kyverna Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Kyverna Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.15 | 7.44 | 4.45 |
| Quick Ratio | 8.15 | 7.44 | 4.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $212.05 Million | $214.36 Million | $41.30 Million |
Kyverna Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Kyverna Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.76 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | $293.83 Million |
| Market Capitalization | $344.71 Million USD |
Valuation Analysis
Above Book Valuation: The market values Kyverna Therapeutics, Inc. Common Stock's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Kyverna Therapeutics, Inc. Common Stock's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $293.83 Million | -3.55% |
| 2024-12-31 | $304.64 Million | +305.14% |
| 2023-12-31 | $75.19 Million | +12.36% |
| 2022-12-31 | $66.92 Million | -21.72% |
| 2021-12-31 | $85.49 Million | -- |
About Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product ca… Read more